RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

Benzinga Newsdesk www.benzinga.com Negative 92.6%

Neg 92.6% Neu 0% Pos 0%

RBC Capital analyst Ben Hendrix reiterates Surgery Partners (NASDAQ:SGRY) with a Outperform and maintains $19 price target.